A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).
Original Article: Blood Test May Predict Palbociclib Response Earlier in Breast Cancer